Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, and biological activities

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4744-4750

  Di Santo, Roberto ^a   Costi, Roberta ^a   Roux, Alessandra ^a   Miele, Gaetano ^a   Crucitti, Giuliana Cuzzucoli ^a   Iacovo, Alberto ^a   Rosi, Federica ^a   Lavecchia, Antonio ^b   Marinelli, Luciana ^b   Di Giovanni, Carmen ^b   Novellino, Ettore ^b   Palmisano, Lucia ^c   Andreotti, Mauro ^c   Amici, Roberta ^c   Galluzzo, Clementina Maria ^c   Nencioni, Lucia ^a   Palamara, Anna Teresa ^a   Pommier, Yves ^d   Marchand, Christophe ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ACETYL 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINONE DERIVATIVE; 3 ACETYL 1 (4 FLUOROPHENYL)METHYL 7 (PYRROLIDIN 1 YL) 4(1H) QUINOLINONE; 3 ACETYL 4(1H) QUINOLINONE DERIVATIVE; 4 [1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [1 (4 FLUOROPHENYL)METHYL 7 (PYRROLIDIN 1 YL) 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [1 (4 FLUOROPHENYL)METHYL 7 (PYRROLIDIN 1 YL) 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [6 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [6 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [6 CHLORO 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [6 CHLORO 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [6 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [6 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [6,7 DICHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [6,7 DICHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [7 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [7 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [7 CHLORO 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [7 CHLORO 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [7 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [7 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [8 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [8 CHLORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; 4 [8 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [8 FLUORO 1 (4 FLUOROPHENYL)METHYL 4(1H) QUINOLINON 3 YL] 2 HYDROXY 4 OXO 2 BUTENOIC ACID ETHYL ESTER; DNA; INTEGRASE INHIBITOR; QUINOLINONYL DIKETO ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DNA STRAND; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CHEMISTRY, PHYSICAL; DRUG DESIGN; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; KETO ACIDS; MOLECULAR STRUCTURE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449093292     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8001422     Document Type: Article

References (19)

1. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
2. Cohen, J. Therapies. Confronting the limits of success. Science 2002, 296, 2320-2324.
3. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency vims integrase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2399-2403.
4. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery 2005, 4, 236-248.
5. Dayam, R.; Gundla, R.; Al-Mawsawi, L. Q.; Neamati, N. HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev. 2008, 28, 118-154.
6. Evering, T. H.; Markowitz, M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today 2007, 43, 865-877.
7. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
8. Cushman, M.; Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem. Biophys. Res. Commun. 1992, 185, 85-90.
9. Carteau, S.; Mouscadet, J.-F.; Goulaouic, H.; Subra, F.; Auclair, C. Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction. Arch. Biochem. Biophys. 1993, 305, 606-610.
10. Pluymers, W.; Neamati, N.; Pannecouque, C.; Fikkert, V.; Marchand, C.; Burke, T. R., Jr.; Pommier, Y.; Schols, D.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 2000, 58, 641-648.
11. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
12. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
13. Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S.; Payne, L. S., Jr.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Witmer, M. V.; Moyer, G.; Schleif, W. A.; Gabryelski, L. J.; Leonard, Y. M., Jr.; Michelson, S. R.; Young, S. D. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456.
14. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A.; Pommier, Y.; Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 2006, 49, 1939-1945.
15. Allison, A. A.; Marchand, C.; Patil, S. S.; Costi, R.; Di Santo, R.; Burke, T. R., Jr.; Pommier, Y. Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays. Mol. Pharmacol. 2007, 71, 893-901.
16. Yoshizawa, H. Process for Producing 5,7-Dichloro-4-hydroxy Quinoline. PCT Int. Appl. WO 9523787, 1995; CAN 124: 29619, 1995.
17. Mapara, R. K.; Desai, C. Synthesis of 4-hydroxyquinolines. J. Indian Chem. Soc. 1954, 31, 951-956.
18. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.
19. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666.